Monte Rosa Therapeutics (GLUE) Enterprise Value (2020 - 2026)

Monte Rosa Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$678.1 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 763.48% year-over-year to -$678.1 million; the TTM figure through Mar 2026 stood at -$678.1 million (down 763.48% YoY), while the FY2025 annual figure was -$129.9 million, up 65.91% from the prior year.
• Enterprise Value was -$678.1 million for Q1 2026 at Monte Rosa Therapeutics, down from -$129.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$47.0 million in Q2 2023 to a low of -$678.1 million in Q1 2026.
• Historically, Enterprise Value has averaged -$158.0 million across 5 years, with a median of -$108.8 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Enterprise Value jumped 82.58% in 2022, then plunged 763.48% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$55.9 million in 2022, then slumped by 323.15% to -$236.4 million in 2023, then plunged by 61.14% to -$381.0 million in 2024, then jumped by 65.91% to -$129.9 million in 2025, then plunged by 422.08% to -$678.1 million in 2026.
• The last three Enterprise Value figures came in at -$678.1 million (Q1 2026), -$129.9 million (Q4 2025), and -$208.3 million (Q3 2025), per Business Quant data.